NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

OS is the "Gold Standard" that is a fact.
Get off the past and focus on the present. NWBO issues with PFS where surpassed by the true
OS results.

PFS and OS basics 101
“Progression-Free Survival (PFS)
Another important endpoint for measuring the effectiveness of cancer drugs is progression-free survival, or PFS – how long a person lives without the disease worsening. PFS results are typically available earlier in a trial than OS data. PFS is considered an indication of disease control and stabilization.
Progressive-Free (PFS)
Measures how long patients live without the disease growing or spreading in the
treatment group compared to a control group.

Overall Survival (OS)
Overall survival, or OS, measures how long patients, who undergo a certain treatment regimen, live compared to patients who are in a control group (i.e., taking either another drug or an inactive treatment, known as a placebo). If a clinical trial demonstrates improved OS, it provides evidence of the drug’s value in prolonging a cancer patient’s life. OS is a strong and precise endpoint, as it requires having more patients and longer follow-ups compared to other clinical trial endpoints. Given all this, OS is often considered the “gold standard” for measuring the clinical benefits of a cancer drug.
Overall Survival (OS)
• Measures how long patients in the treatment group live compared to a controlled group.
• Is known as the gold standard in oncology clinical trials. “
Source
https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/clinical-trial-endpoints-in-cancer-research-four-terms-you-should-know-09242018.html#